A revenue-generating, small-cap Canadian pharmaceutical company
Revenue Projected at $150,000,000 by 2025
Message: VALEO PHARMA TO HOST THIRD QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL , Sept. 9, 2022 /CNW Telbec/ - Valeo Pharma Inc . (VPH: TSX) (VPHIF: OTCQB) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2022 on Tuesday September 13, 2022 after market close. The Company will host a conference call to discuss those results and highlights on Wednesday September 14, 2022 at 8.30am (ET) .
|
Conference ID: |
38670463 |
|
Date: |
Wednesday, September 14, 2022 |
|
Time: |
8:30am ET |
|
Dial-in numbers: |
1-888-664-6392 or 416-764-8659 |
|
Audio replay numbers: |
1-888-390-0541 or 416-764-8677 |
|
Replay code: |
670463# |
A live audio webcast of the conference call will be available via:
https://app.webinar.net/bKVqJ5MJrgD
About Valeo Pharma Inc.
Valeo Pharma is a fast growing Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .
Forward Looking Statements
This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
SOURCE Valeo Pharma Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2022/09/c6657.html
Source: Canada Newswire (September 9, 2022 - 7:00 AM EDT)
New Message
Please
login
to post a reply